This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Patheon BV
Patheon BV, a leading contract development and manufacturing organisation (CDMO), is headquartered in the United States and operates extensively across Europe and Asia. Founded in 1974, Patheon has established itself as a key player in the pharmaceutical and biotechnology industries, specialising in drug development, manufacturing, and delivery solutions. The company offers a comprehensive range of services, including formulation development, clinical trial manufacturing, and commercial production, distinguished by its commitment to quality and innovation. Patheon’s state-of-the-art facilities and advanced technologies enable it to meet the diverse needs of its clients, ensuring efficient and reliable product delivery. With a strong market position, Patheon BV has achieved notable milestones, including strategic partnerships and expansions that enhance its global footprint. Its dedication to excellence has solidified its reputation as a trusted partner for pharmaceutical companies seeking to bring life-saving therapies to market.
DitchCarbon Score
How does Patheon BV's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Patheon BV's score of 70 is higher than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Patheon BV, headquartered in the US, currently does not report specific carbon emissions data, as no figures are available. However, the company is part of a corporate family relationship with Thermo Fisher Scientific Inc., which cascades its climate commitments and performance metrics to Patheon BV. Thermo Fisher Scientific Inc. has established various climate initiatives, including Science Based Targets Initiative (SBTi) commitments and participation in the Carbon Disclosure Project (CDP). These initiatives aim to enhance sustainability and reduce carbon footprints across their operations. As a current subsidiary of Thermo Fisher Scientific Inc., Patheon BV aligns with these broader corporate sustainability goals, although specific reduction targets or achievements for Patheon BV itself have not been disclosed. The absence of direct emissions data highlights the need for ongoing transparency and commitment to climate action within the pharmaceutical manufacturing sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 321,190,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 486,151,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Patheon BV is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
